STOCK TITAN

Fortrea (FTRE) Insider Notice: 4,886 Shares to Be Sold via Fidelity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Form 144 for Fortrea Holdings, Inc. (FTRE) shows a proposed sale of 4,886 common shares with an aggregate market value of $39,160.31, to be sold on or about 08/19/2025 through Fidelity Brokerage Services LLC on NASDAQ. The shares were acquired on 08/18/2025 upon restricted stock vesting and the payment type is listed as compensation. The filing reports 90,800,000 shares outstanding. It also discloses a prior sale by the same person of 3,130 shares on 06/03/2025 for $13,049.91. The filer certifies they are not aware of undisclosed material adverse information.

Positive

  • Clear disclosure of acquisition method: shares were acquired via restricted stock vesting, clarifying the basis for the sale
  • Fulfills reporting obligations by disclosing broker, intended sale date, and recent prior sale, supporting regulatory transparency

Negative

  • None.

Insights

TL;DR: Small, routine insider sale following restricted stock vesting; immaterial to market given the outstanding share count.

The notice documents a typical post-vesting sale of 4,886 shares valued at $39,160.31 to be executed through Fidelity. Compared with the reported 90.8 million shares outstanding, this transaction is negligible in size and unlikely to move the market or alter ownership control. The filing and prior sale disclosure (3,130 shares on 06/03/2025) are consistent with standard reporting obligations for insiders converting compensation into marketable shares.

TL;DR: Filing appears procedurally compliant; the signer affirms no undisclosed material information.

The document specifies acquisition method (restricted stock vesting), payment as compensation, broker details, and prior sales, addressing key Rule 144 disclosure elements. There is an explicit representation that the seller does not possess undisclosed material adverse information. From a compliance perspective this is a routine disclosure with no red flags in the provided fields, though further verification would require reviewing the completed signature block and filing attachments which are not present here.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 for FTRE disclose about the upcoming sale?

It discloses an intended sale of 4,886 common shares valued at $39,160.31, expected on or about 08/19/2025 through Fidelity on NASDAQ.

How were the FTRE shares acquired that are proposed for sale?

The shares were acquired on 08/18/2025 through restricted stock vesting and the nature of payment is listed as compensation.

Has the seller of FTRE shares reported recent sales in the past three months?

Yes. The filing lists a prior sale of 3,130 common shares on 06/03/2025 for $13,049.91.

How large is the proposed sale relative to Fortrea's outstanding shares?

The proposed sale of 4,886 shares is small versus the reported 90,800,000 shares outstanding, indicating immaterial ownership change.

Does the filer assert they have undisclosed material information about FTRE?

The filer represents by signing the notice that they do not know any material adverse information about the issuer that has not been publicly disclosed.
Fortrea Holdings

NASDAQ:FTRE

FTRE Rankings

FTRE Latest News

FTRE Latest SEC Filings

FTRE Stock Data

1.61B
91.87M
0.5%
111.46%
11.57%
Biotechnology
Services-medical Laboratories
Link
United States
DURHAM